Biora Therapeutics Inc (OTCPK:BIOR)

$ 0.22 0 (0%) Market Cap: 995,000.00 Enterprise Value: 37.45 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Q2 2024 Biora Therapeutics Inc Earnings Call Transcript
Aug 12, 2024

$5.83 (-1.35%)

Earnings
Q1 2024 Biora Therapeutics Inc Earnings Call Transcript
May 15, 2024

$7.15 (-3.10%)

Earnings
Q4 2023 Biora Therapeutics Inc Earnings Call Transcript
Mar 26, 2024

$13.3 (+9.02%)

Earnings
Q3 2023 Biora Therapeutics Inc Earnings Call Transcript
Nov 13, 2023

$13.7 (-3.52%)

Earnings
Q2 2023 Biora Therapeutics Inc Earnings Call Transcript
Aug 14, 2023

$31.7 (-8.38%)

Earnings
Biora Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 14, 2023
Q1 2023 Biora Therapeutics Inc Earnings Call Transcript
May 15, 2023

$33.5 (-10.90%)

Earnings
Q4 2022 Biora Therapeutics Inc Earnings Call Transcript
Mar 30, 2023

$26.7 (+0.75%)

Earnings
Biora Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Dec 19, 2022
Q3 2022 Biora Therapeutics Inc Earnings Call Transcript
Nov 14, 2022

$70.28 (+0.75%)

Earnings
Q2 2022 Biora Therapeutics Inc Earnings Call Transcript
Aug 15, 2022

$260 (+4.00%)

Earnings
Biora Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 15, 2022
Q1 2022 Biora Therapeutics Inc Earnings Call Transcript
May 10, 2022

$192.73 (+1.43%)

Earnings
Q4 2021 Progenity Inc Earnings Call Transcript
Mar 28, 2022

$402.5 (-4.73%)

Earnings
Q3 2021 Progenity Inc Earnings Call Transcript
Nov 10, 2021

$880 (+3.23%)

Earnings
Q2 2021 Progenity Inc Earnings Call Transcript
Aug 12, 2021

$435 (-3.87%)

Earnings
Progenity Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
Progenity Inc Call to Discuss Strategic Transformation Transcript
Jun 02, 2021
Q1 2021 Progenity Inc Earnings Call Transcript
May 13, 2021

$587.5 (-1.67%)

Earnings
Q4 2020 Progenity Inc Earnings Call Transcript
Mar 18, 2021

$1097.5 (-11.85%)

Earnings
Progenity Inc Preeclampsia Virtual R&D Day Transcript
Nov 20, 2020
Q3 2020 Progenity Inc Earnings Call Transcript
Nov 09, 2020

$1217.5 (-0.20%)

Earnings
Q2 2020 Progenity Inc Earnings Call Transcript
Aug 13, 2020

$2237.5 (-1.97%)

Earnings

Progenity Inc Preeclampsia Virtual R&D Day Transcript

Nov 20, 2020 / 04:00PM GMT

Release Date Price: $980 (-2.00%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Progenity Preeclampsia Virtual R&D Day Conference Call. (Operator Instructions)

I would now like the hand the conference to your speaker today, Dr. Matthew Cooper. Please go ahead, sir.

Matthew Cooper

Progenity, Inc. - Chief Scientific Officer

All right, thank you, Operator. Good morning, everyone, and welcome to Progenity's Preeclampsia R&D Day. Before we get into the program, I must remind you that we'll be making forward-looking statements and for an explanation of the risks and uncertainties associated with those statements, I invite you to review the legal disclaimer shown here on slide two.

So with that out of the way, let's dive in, shall we? I'd like to kick us off by going over the key points we would like for you to take home from the program today.

The focus of R&D Day will be Preecludia, our new brand name for our preeclampsia product. Preecludia addresses a large unmet medical need and aiding physicians in ruling out preeclampsia in mothers

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.